{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:07:58Z","timestamp":1791806878531,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF\u20102021R1A6A1A03040260"],"award-info":[{"award-number":["NRF\u20102021R1A6A1A03040260"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF\u20102022R1A2C3008956"],"award-info":[{"award-number":["NRF\u20102022R1A2C3008956"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Tumour microenvironment heterogeneity among different organs can influence immunotherapy responses. Here, we evaluated the impact of differential organ\u2010specific responses on survival in patients with advanced\u2010stage hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo\/Bev).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 366 consecutive patients with advanced\u2010stage HCC treated with Atezo\/Bev as first\u2010line systemic treatment. Therapeutic response was assessed using RECIST v1.1. Patients were divided into an intention\u2010to\u2010treat (ITT) group (patients treated with \u22651\u2009dose of Atezo\/Bev) and a per\u2010protocol (PP) analysis group (patients with at least one measurable lesion irrespective of location treated with \u22653\u2009doses of Atezo\/Bev). Overall response and organ\u2010specific response at initial and best response were evaluated in the PP group. Responders were defined as patients achieving complete remission or partial response. Initial progressors were defined as patients with progressive disease after three doses of Atezo\/Bev.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ITT and PP groups comprised 324 and 236 patients, respectively. In the PP group, the organ\u2010specific response rate of lung and lymph node (LN) metastases at both initial and best responses were higher than those of intrahepatic lesions and macrovascular tumour thrombosis. Lung and LN\u2010specific response rates were 21.1% and 23.5%, respectively, at initial response, and 24.7% and 31.4%, respectively, at best response. Both initial pulmonary and lymphatic progressors (adjusted hazard ratios [95% confidence intervals], 6.37 [2.10\u201319.3], and 8.36 [2.16\u201332.4], respectively) were independently associated with survival regardless of intrahepatic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The response of metastatic HCC to the Atezo\/Bev regimen may be used to determine whether to continue treatment or switch to second\u2010line treatment at an early phase of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.15826","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T02:40:05Z","timestamp":1706668805000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with\n                    <scp>HCC<\/scp>"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1577-1759","authenticated-orcid":false,"given":"Jiwon","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-5850","authenticated-orcid":false,"given":"Jonggi","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-1765","authenticated-orcid":false,"given":"Won\u2010Mook","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3180-3178","authenticated-orcid":false,"given":"Kang Mo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-4124","authenticated-orcid":false,"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-1371","authenticated-orcid":false,"given":"Ju Hyun","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"e_1_2_14_3_1","unstructured":"National Comprehensive Cancer Network.Hepatocellular carcinoma (version 1. 2023).2023https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdfAccessed June 26 2023."},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2022.11.07"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2239-4"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1366"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501275"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000491"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1138"},{"key":"e_1_2_14_13_1","unstructured":"Liver Cancer Center AMC.Medical specialites: AMC's treatment performance.2017.https:\/\/eng.amc.seoul.kr\/gb\/lang\/specialities\/illness.do?code=CA_Liver_Cancer. Accessed July 15 2023."},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249426"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000505933"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-023-03827-y"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15102"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)01389-2"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5578-4"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14913"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.065"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02648-y"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12540"},{"issue":"6","key":"e_1_2_14_28_1","first-page":"2079","article-title":"Expression and clinical significance of PD\u20101 in hepatocellular carcinoma tissues detected by a novel mouse anti\u2010human PD\u20101 monoclonal antibody","volume":"52","author":"Li Z","year":"2018","journal-title":"Int J Oncol"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28710"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506352"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15051"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.04.019"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041896"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00274-z"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2014.05.002"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T09:55:03Z","timestamp":1711101303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/liv.15826"],"URL":"https:\/\/doi.org\/10.1111\/liv.15826","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"2023-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}